- Home
- SLXN vs BCLI Comparison
SLXN vs BCLI Comparison
Compare SLXN & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- BCLI
- Stock Information
- Founded
- SLXN 2008
- BCLI 2000
- Country
- SLXN Israel
- BCLI United States
- Employees
- SLXN N/A
- BCLI N/A
- Industry
- SLXN
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLXN
- BCLI Health Care
- Exchange
- SLXN NYSE
- BCLI Nasdaq
- Market Cap
- SLXN 6.9M
- BCLI 7.9M
- IPO Year
- SLXN N/A
- BCLI N/A
- Fundamental
- Price
- SLXN $0.92
- BCLI $1.32
- Analyst Decision
- SLXN Strong Buy
- BCLI Strong Buy
- Analyst Count
- SLXN 1
- BCLI 1
- Target Price
- SLXN $5.00
- BCLI $30.00
- AVG Volume (30 Days)
- SLXN 3.6M
- BCLI 145.7K
- Earning Date
- SLXN 05-13-2025
- BCLI 05-15-2025
- Dividend Yield
- SLXN N/A
- BCLI N/A
- EPS Growth
- SLXN N/A
- BCLI N/A
- EPS
- SLXN N/A
- BCLI N/A
- Revenue
- SLXN N/A
- BCLI N/A
- Revenue This Year
- SLXN N/A
- BCLI N/A
- Revenue Next Year
- SLXN N/A
- BCLI N/A
- P/E Ratio
- SLXN N/A
- BCLI N/A
- Revenue Growth
- SLXN N/A
- BCLI N/A
- 52 Week Low
- SLXN $0.21
- BCLI $0.72
- 52 Week High
- SLXN $13.56
- BCLI $10.05
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- BCLI 59.70
- Support Level
- SLXN N/A
- BCLI $1.10
- Resistance Level
- SLXN N/A
- BCLI $1.26
- Average True Range (ATR)
- SLXN 0.00
- BCLI 0.14
- MACD
- SLXN 0.00
- BCLI 0.02
- Stochastic Oscillator
- SLXN 0.00
- BCLI 75.00
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.